Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Safiglipron

Stage Phase 3Stale

Sponsor Shandong Suncadia Medicine Co

Route oral

Class Oral small molecule

Mechanism oral small-molecule GLP-1 receptor agonist

Sources

registry, as of 2026-09-24Stale

https://clinicaltrials.gov/study/NCT07528027

Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity. Overall status RECRUITING. Phases PHASE3. Lead sponsor Shandong Suncadia Medicine Co., Ltd.. Enrollment 648. Conditions Hypertension With Overweight or Obesity. The main objective of this study is to demonstrate the superior efficacy of HRS-7535 in controlling blood pressure compared to placebo in subjects with hypertension and overweight or obesity;

ClinicalTrials.gov NCT07528027 protocol and results modules

registry, as of 2026-07-27Stale

https://clinicaltrials.gov/study/NCT06904105

A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Shandong Suncadia Medicine Co., Ltd.. Enrollment 556. Conditions Overweight; Obesity. The study is being conducted to evaluate the efficacy and safety of HRS-7535 in subjects with overweight or obesity.

ClinicalTrials.gov NCT06904105 protocol and results modules

registry, as of 2025-04-13Stale

https://clinicaltrials.gov/study/NCT06250946

Efficacy and Safety of HRS-7535 Tablets in Obese Subjects .. Overall status COMPLETED. Phases PHASE2. Lead sponsor Shandong Suncadia Medicine Co., Ltd.. Enrollment 235. Conditions Overweight and Obesity. The aim of this trial is to evaluate the efficacy and safety of HRS-7535 in Chinese Obese Subjects.

ClinicalTrials.gov NCT06250946 protocol and results modules

registry, as of 2025-12-29Stale

https://clinicaltrials.gov/study/NCT06820099

Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity. Overall status RECRUITING. Phases PHASE2. Lead sponsor Shandong Suncadia Medicine Co., Ltd.. Enrollment 225. Conditions Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity. This is a multicenter, randomized, double-blind, placebo-controlled, parallel design phase II clinical trial, including a screening period of up to 2 weeks, a 36-weeks' treatment period, and a 1-week safety follow-up visit period.

ClinicalTrials.gov NCT06820099 protocol and results modules

registry, as of 2025-11-17Stale

https://clinicaltrials.gov/study/NCT06671821

Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor Shandong Suncadia Medicine Co., Ltd.. Enrollment 81. Conditions Chronic Weight Management. The Objective of this trial is to evaluate the long-term safety, tolerability, weight loss efficacy and metabolic benefits of HRS-7535 tablets inobesity.

ClinicalTrials.gov NCT06671821 protocol and results modules

registry, as of 2026-08-24Stale

https://clinicaltrials.gov/study/NCT06621316

A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor Shandong Suncadia Medicine Co., Ltd.. Enrollment 74. Conditions Overweight or Obesity. The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of HRS-7535 tablet in obese subjects.

ClinicalTrials.gov NCT06621316 protocol and results modules

registry, as of 2026-06-29Stale

https://clinicaltrials.gov/study/NCT07269756

A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects. Overall status COMPLETED. Phases PHASE1. Lead sponsor Shandong Suncadia Medicine Co., Ltd.. Enrollment 40. Conditions Obesity; Overweight. This study is an open-label, fixed-sequence, self-controlled Phase I clinical trial conducted among obese or overweight subjects, with a planned enrollment of 40 adult subjects.

ClinicalTrials.gov NCT07269756 protocol and results modules

publication, as of 2026-08-05Stale

https://pubmed.ncbi.nlm.nih.gov/42331800/

without diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. HRS-7535 is an orally active small-molecule glucagon-like peptide-1 receptor agonist that showed weight-loss potential in a phase 1 study. In this completed multicenter, randomized, double-blind, placebo-controlled phase 2 trial conducted at 29 centers in China, w

PMID 42331800

Studies

Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity

Registry NCT07528027

Phase Phase 3

Status Recruiting

Enrollment 648

Start 2026-05-29

Treatment group A: HRS-7535

Comparator placebo

Population Hypertension With Overweight or Obesity

Treatment group B: Placebo

Population Hypertension With Overweight or Obesity

A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity

Registry NCT06904105

Phase Phase 3

Status Completed

Enrollment 556

Start 2025-04-10

Primary completion 2026-04-17

Study completion 2026-06-12

Catalyst Primary completion. 2026-04-17. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

HRS-7535 Group

Comparator placebo

Population Overweight; Obesity

HRS-7535 Placebo Group

Population Overweight; Obesity

Efficacy and Safety of HRS-7535 Tablets in Obese Subjects .

Registry NCT06250946

Phase Phase 2

Status Completed

Enrollment 235

Start 2024-02-23

Primary completion 2025-01-22

Study completion 2025-01-22

Catalyst Primary completion. 2025-01-22. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Group A

Comparator placebo

Population Overweight and Obesity

Group B

Comparator placebo

Population Overweight and Obesity

Group C

Comparator placebo

Population Overweight and Obesity

Group D

Comparator placebo

Population Overweight and Obesity

Group E

Population Overweight and Obesity

Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity

Registry NCT06820099

Phase Phase 2

Status Recruiting

Enrollment 225

Start 2025-04-10

Treatment group A

Comparator placebo

Population Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity

Treatment group B

Population Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity

Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects

Registry NCT06671821

Phase Phase 2

Status Completed

Enrollment 81

Start 2024-11-20

Primary completion 2025-08-15

Study completion 2025-09-28

Catalyst Primary completion. 2025-08-15. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Group A

Population Chronic Weight Management

Group B

Population Chronic Weight Management

Group C

Population Chronic Weight Management

Group D

Population Chronic Weight Management

A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects

Registry NCT06621316

Phase Phase 1/2

Status Completed

Enrollment 74

Start 2024-10-30

Primary completion 2025-07-14

Study completion 2025-07-14

Catalyst Primary completion. 2025-07-14. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Treatment group A

Comparator placebo

Population Overweight or Obesity

Treatment group B

Comparator placebo

Population Overweight or Obesity

Treatment group C

Comparator placebo

Population Overweight or Obesity

Treatment group D

Comparator placebo

Population Overweight or Obesity

Treatment group E

Population Overweight or Obesity

Treatment group F

Population Overweight or Obesity

Treatment group G

Population Overweight or Obesity

Treatment group H

Population Overweight or Obesity

Treatment group I

Comparator placebo

Population Overweight or Obesity

Treatment group J

Comparator placebo

Population Overweight or Obesity

Treatment group K

Population Overweight or Obesity

Treatment group L

Population Overweight or Obesity

A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects

Registry NCT07269756

Phase Phase 1

Status Completed

Enrollment 40

Start 2025-12-07

Primary completion 2026-03-08

Study completion 2026-03-08

Catalyst Primary completion. 2026-03-08. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Oral Medication Group

Population Obesity; Overweight